SeaCrest Wealth Management’s Seres Therapeutics MCRB Stock Holding History

SeaCrest Wealth Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50	Closed	-$9K	–	2296
2018 Q2	$9K	Hold	50	–	–	﹤0.01%	1662
2018 Q1	$7K	Hold	50	–	–	﹤0.01%	1700
2017 Q4	$10K	Buy	+50	New	+$10.3K	﹤0.01%	1594

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SeaCrest Wealth Management's MCRB Position: Q3 2018 in Review

SeaCrest Wealth Management sold out of Seres Therapeutics (MCRB) in Q3 2018, closing a stake of 50 shares — an estimated $9K sold.

SeaCrest Wealth Management first reported a position in MCRB in Q4 2017 and held it in 3 quarters. The position peaked at $10K in Q4 2017. 72 funds tracked by Wall St. Rank hold MCRB as of Q3 2018.

SeaCrest Wealth Management reported no remaining Seres Therapeutics position as of Q3 2018 after selling out during the quarter.
SeaCrest Wealth Management sold 50 Seres Therapeutics shares in Q3 2018, an estimated $9K.
SeaCrest Wealth Management first reported a position in Seres Therapeutics in Q4 2017 and held it in 3 quarters.
SeaCrest Wealth Management's Seres Therapeutics position peaked at $10K in Q4 2017.
72 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2018.

Based on SeaCrest Wealth Management's 13F filing for Q3 2018, filed 14 Nov 2018.